Artificial intelligence (AI) is playing an ever-increasing role in clinical trial recruitment, design, prediction and delivery. Whether it’s mining electronic health records, clinical data, imaging and disease registries, listening to patient reported outcomes on social media, recruiting to trials via social networking sites like Facebook or even predicting outcomes, artificial intelligence and new social networking technologies are rapidly gaining traction and momentum in this sector. Real world data, particularly that generated by patients and carers, is now being used in novel ways, helping us to better understand the real lived experience of patients and carers and in designing more patient-centric clinical interventions, engagement, compliance, retention and research opportunities.
Despite the apparent benefits of these new approaches, there are a number of significant ethical considerations and challenges, as well as adjustments likely to be required to regulatory frameworks as these technologies evolve and the social licence to operate is continuously negotiated. What are the AI data-centric approaches currently in play and entering the sector, and how can we best optimise these emerging platforms to drive more effective recruitment, improve trial design and delivery and be more inclusive of different clinical trials populations across all Australian regions, whilst ensuring compliance and the frameworks for valid informed consent are upheld.
Michelle Gallaher , CEO Opyl AI